Want to see JP:4591 full AI Analyst Report?
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥57.00 - ¥127.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)477.44K
Market Cap
¥4.36B
Enterprise Value¥1.55B
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.34
Shares Outstanding56,572,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)1.54
Price to Sales (P/S)1456.29
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA net-cash, zero-debt posture materially reduces financial distress risk and gives management flexibility to fund R&D or operations without immediate refinancing. This durable financial buffer supports a multi-quarter development runway versus leveraged peers and eases downside risk.
Proprietary Aptamer PlatformA proprietary platform focused on aptamer discovery provides a structural competitive advantage: platform scalability can generate multiple drug candidates, enable partner licensing, and concentrate R&D expertise. This durable intellectual property orientation supports long-term optionality.
Recent Revenue ReboundA sharp rebound in revenue, even from a small base, signals early commercial traction or successful milestone monetization. Sustained top-line growth can gradually improve leverage of R&D spend, strengthen partnerships, and reduce absolute funding needs over several quarters.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow depletes cash reserves and shortens runway absent financing. Over time this raises dilution and financing risk, forces prioritization of projects, and constrains strategic optionality unless cash generation materially improves.
Deep UnprofitabilityLarge recurring operating and net losses mean margins are structurally negative relative to expenses. Persisting unprofitability erodes equity, increases dependency on external capital, and extends the timeline to sustainable returns, raising long-term investor risk.
No Marketed Products / Development RiskAbsence of approved products makes company value contingent on clinical and regulatory milestones. This creates binary, long-dated execution risk: delays or failures materially impair revenue prospects and increase financing needs over multiple quarters.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥57.00 and its highest was ¥127.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥4.36B.
When is Ribomic, Inc.’s upcoming earnings report date?
Ribomic, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Ribomic, Inc.’s earnings last quarter?
Ribomic, Inc. released its earnings results on May 14, 2026. The company reported -¥7.21 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.21.
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 56,572,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Ribomic, Inc. reported an EPS of -¥7.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.